 Leigh Perreault
Concepts (332)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prediabetic State | 24 | 2024 | 245 | 6.910 |
Why?
| | Diabetes Mellitus, Type 2 | 50 | 2024 | 2430 | 5.090 |
Why?
| | Insulin Resistance | 32 | 2024 | 1166 | 3.750 |
Why?
| | Hypoglycemic Agents | 23 | 2023 | 1214 | 3.270 |
Why?
| | Obesity | 29 | 2024 | 2860 | 2.810 |
Why?
| | Blood Glucose | 31 | 2023 | 2092 | 2.630 |
Why?
| | Weight Loss | 15 | 2024 | 723 | 2.250 |
Why?
| | Muscle, Skeletal | 21 | 2024 | 1639 | 2.220 |
Why?
| | Cardiovascular Diseases | 15 | 2020 | 2018 | 2.060 |
Why?
| | Insulin | 20 | 2024 | 2318 | 1.880 |
Why?
| | Sphingolipids | 7 | 2024 | 69 | 1.720 |
Why?
| | Diabetes Mellitus | 11 | 2023 | 1001 | 1.660 |
Why?
| | Triglycerides | 11 | 2024 | 524 | 1.590 |
Why?
| | Benzhydryl Compounds | 3 | 2017 | 65 | 1.480 |
Why?
| | Glucose Intolerance | 8 | 2020 | 142 | 1.460 |
Why?
| | Diabetic Angiopathies | 3 | 2017 | 263 | 1.440 |
Why?
| | Diglycerides | 6 | 2024 | 61 | 1.320 |
Why?
| | Overweight | 7 | 2022 | 525 | 1.130 |
Why?
| | Diabetes Complications | 2 | 2019 | 224 | 1.130 |
Why?
| | Glucosides | 2 | 2017 | 37 | 1.100 |
Why?
| | Glucagon-Like Peptide 1 | 3 | 2023 | 113 | 1.030 |
Why?
| | Life Style | 12 | 2020 | 459 | 1.020 |
Why?
| | Metformin | 13 | 2023 | 311 | 0.930 |
Why?
| | Primary Health Care | 6 | 2023 | 1638 | 0.920 |
Why?
| | Exercise | 11 | 2024 | 1937 | 0.890 |
Why?
| | Receptors, Gastrointestinal Hormone | 1 | 2023 | 6 | 0.880 |
Why?
| | Anti-Obesity Agents | 2 | 2024 | 53 | 0.860 |
Why?
| | Glucose Tolerance Test | 15 | 2021 | 356 | 0.860 |
Why?
| | Glucose Clamp Technique | 11 | 2024 | 195 | 0.820 |
Why?
| | Goals | 2 | 2021 | 162 | 0.810 |
Why?
| | Humans | 94 | 2024 | 128524 | 0.780 |
Why?
| | Adult | 54 | 2024 | 35315 | 0.780 |
Why?
| | Health Equity | 1 | 2023 | 79 | 0.760 |
Why?
| | Nutrition Therapy | 1 | 2022 | 31 | 0.760 |
Why?
| | Middle Aged | 45 | 2024 | 30893 | 0.750 |
Why?
| | Liver | 4 | 2014 | 1827 | 0.730 |
Why?
| | Adipose Tissue | 4 | 2023 | 591 | 0.700 |
Why?
| | Hyperglycemia | 4 | 2014 | 325 | 0.680 |
Why?
| | Primary Care Nursing | 1 | 2019 | 4 | 0.670 |
Why?
| | Male | 59 | 2024 | 62883 | 0.640 |
Why?
| | Female | 64 | 2024 | 68127 | 0.630 |
Why?
| | Microvessels | 1 | 2019 | 79 | 0.610 |
Why?
| | Obesity Management | 1 | 2018 | 8 | 0.610 |
Why?
| | Insulin, Long-Acting | 1 | 2019 | 61 | 0.610 |
Why?
| | Peripheral Vascular Diseases | 1 | 2019 | 104 | 0.610 |
Why?
| | Infant, Newborn, Diseases | 1 | 2019 | 108 | 0.590 |
Why?
| | Body Mass Index | 12 | 2024 | 2262 | 0.590 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 1 | 2019 | 91 | 0.590 |
Why?
| | Awareness | 1 | 2019 | 99 | 0.590 |
Why?
| | Fasting | 4 | 2020 | 263 | 0.570 |
Why?
| | Ceramides | 5 | 2024 | 104 | 0.560 |
Why?
| | Precision Medicine | 1 | 2021 | 383 | 0.560 |
Why?
| | Policy | 1 | 2018 | 144 | 0.550 |
Why?
| | Risk Factors | 19 | 2023 | 9727 | 0.540 |
Why?
| | Weight Reduction Programs | 2 | 2017 | 111 | 0.540 |
Why?
| | Risk Management | 1 | 2017 | 90 | 0.530 |
Why?
| | Incretins | 2 | 2021 | 18 | 0.530 |
Why?
| | Rest | 2 | 2017 | 123 | 0.520 |
Why?
| | Choristoma | 1 | 2015 | 21 | 0.500 |
Why?
| | Sleep Deprivation | 5 | 2021 | 171 | 0.490 |
Why?
| | Insulin-Secreting Cells | 2 | 2010 | 365 | 0.470 |
Why?
| | Weight Gain | 4 | 2019 | 505 | 0.440 |
Why?
| | Lipid Metabolism | 4 | 2021 | 493 | 0.430 |
Why?
| | Sarcolemma | 3 | 2024 | 40 | 0.420 |
Why?
| | Lipids | 4 | 2024 | 624 | 0.420 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2022 | 1358 | 0.410 |
Why?
| | Glucose | 4 | 2023 | 983 | 0.410 |
Why?
| | Phenols | 1 | 2013 | 96 | 0.400 |
Why?
| | Clinical Trials as Topic | 1 | 2017 | 998 | 0.400 |
Why?
| | Physical Endurance | 5 | 2020 | 269 | 0.370 |
Why?
| | Glucagon-Like Peptides | 2 | 2022 | 51 | 0.360 |
Why?
| | Fenofibrate | 1 | 2011 | 31 | 0.360 |
Why?
| | Athletes | 7 | 2024 | 410 | 0.350 |
Why?
| | Hypolipidemic Agents | 1 | 2011 | 93 | 0.340 |
Why?
| | Cross-Sectional Studies | 9 | 2024 | 5040 | 0.340 |
Why?
| | Palmitates | 1 | 2009 | 18 | 0.340 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2010 | 45 | 0.340 |
Why?
| | Phosphatidylcholines | 2 | 2024 | 146 | 0.340 |
Why?
| | Aged | 17 | 2023 | 21971 | 0.330 |
Why?
| | Hospitalization | 1 | 2019 | 2071 | 0.330 |
Why?
| | Pyrazines | 1 | 2010 | 88 | 0.330 |
Why?
| | Triazoles | 1 | 2010 | 151 | 0.310 |
Why?
| | Sleep | 4 | 2021 | 672 | 0.310 |
Why?
| | Energy Metabolism | 4 | 2021 | 836 | 0.310 |
Why?
| | Biomarkers | 8 | 2023 | 3881 | 0.300 |
Why?
| | Sodium-Glucose Transporter 2 | 2 | 2017 | 22 | 0.280 |
Why?
| | Risk Reduction Behavior | 3 | 2023 | 208 | 0.280 |
Why?
| | Sex Characteristics | 3 | 2021 | 727 | 0.270 |
Why?
| | Diabetic Nephropathies | 2 | 2020 | 277 | 0.270 |
Why?
| | Markov Chains | 2 | 2018 | 116 | 0.270 |
Why?
| | Double-Blind Method | 5 | 2024 | 1860 | 0.270 |
Why?
| | Absenteeism | 2 | 2018 | 49 | 0.260 |
Why?
| | Sex Factors | 5 | 2018 | 1949 | 0.260 |
Why?
| | Health Services | 2 | 2018 | 103 | 0.260 |
Why?
| | Adiponectin | 3 | 2018 | 234 | 0.250 |
Why?
| | Pilot Projects | 2 | 2021 | 1558 | 0.250 |
Why?
| | Circadian Rhythm | 3 | 2019 | 405 | 0.240 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2022 | 564 | 0.240 |
Why?
| | Follow-Up Studies | 6 | 2021 | 4898 | 0.240 |
Why?
| | Muscle Fibers, Skeletal | 3 | 2024 | 190 | 0.240 |
Why?
| | Remission Induction | 3 | 2019 | 269 | 0.240 |
Why?
| | Young Adult | 12 | 2024 | 12320 | 0.230 |
Why?
| | Carnitine | 2 | 2024 | 76 | 0.230 |
Why?
| | Dietary Fats | 3 | 2020 | 301 | 0.220 |
Why?
| | Lipogenesis | 2 | 2017 | 59 | 0.220 |
Why?
| | Lipoprotein Lipase | 1 | 2004 | 58 | 0.220 |
Why?
| | Hyperinsulinism | 1 | 2024 | 119 | 0.210 |
Why?
| | Oxidation-Reduction | 4 | 2024 | 1001 | 0.210 |
Why?
| | Physical Exertion | 1 | 2004 | 212 | 0.210 |
Why?
| | Healthy Lifestyle | 1 | 2023 | 32 | 0.210 |
Why?
| | Computer Simulation | 2 | 2018 | 939 | 0.200 |
Why?
| | Socioeconomic Factors | 2 | 2018 | 1197 | 0.200 |
Why?
| | Energy Intake | 4 | 2021 | 453 | 0.200 |
Why?
| | Diet, Reducing | 3 | 2017 | 84 | 0.200 |
Why?
| | Consensus | 3 | 2020 | 633 | 0.200 |
Why?
| | Biopsy | 3 | 2018 | 1085 | 0.190 |
Why?
| | Combined Modality Therapy | 4 | 2019 | 1209 | 0.190 |
Why?
| | Prevalence | 2 | 2019 | 2549 | 0.190 |
Why?
| | Cluster Analysis | 1 | 2023 | 478 | 0.190 |
Why?
| | Endpoint Determination | 2 | 2019 | 75 | 0.190 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2024 | 1943 | 0.190 |
Why?
| | Nephrology | 1 | 2022 | 60 | 0.180 |
Why?
| | Glucose Transporter Type 4 | 1 | 2021 | 39 | 0.180 |
Why?
| | Cytosol | 2 | 2020 | 213 | 0.180 |
Why?
| | Ambulatory Care Facilities | 1 | 2023 | 227 | 0.180 |
Why?
| | Body Weight | 4 | 2024 | 931 | 0.170 |
Why?
| | Risk Adjustment | 1 | 2020 | 79 | 0.170 |
Why?
| | Endocrinologists | 1 | 2020 | 12 | 0.170 |
Why?
| | New Zealand | 1 | 2019 | 45 | 0.170 |
Why?
| | Cytosine | 1 | 2019 | 45 | 0.160 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2019 | 62 | 0.160 |
Why?
| | Endoplasmic Reticulum | 2 | 2020 | 260 | 0.160 |
Why?
| | Fatty Liver | 1 | 2021 | 232 | 0.160 |
Why?
| | Liraglutide | 1 | 2019 | 29 | 0.160 |
Why?
| | Fatty Acids, Nonesterified | 2 | 2019 | 159 | 0.160 |
Why?
| | Exercise Test | 3 | 2015 | 615 | 0.150 |
Why?
| | Models, Econometric | 1 | 2018 | 34 | 0.150 |
Why?
| | Retinal Diseases | 1 | 2019 | 86 | 0.150 |
Why?
| | Adolescent | 8 | 2023 | 20213 | 0.150 |
Why?
| | Postprandial Period | 1 | 2019 | 102 | 0.150 |
Why?
| | United States | 9 | 2023 | 13876 | 0.150 |
Why?
| | Quinolizines | 1 | 1997 | 8 | 0.150 |
Why?
| | Colorado | 3 | 2023 | 4392 | 0.140 |
Why?
| | Drug Combinations | 1 | 2019 | 323 | 0.140 |
Why?
| | Referral and Consultation | 1 | 2023 | 727 | 0.140 |
Why?
| | Antiemetics | 1 | 1997 | 39 | 0.140 |
Why?
| | Tissue Plasminogen Activator | 2 | 2018 | 220 | 0.140 |
Why?
| | Nausea | 1 | 1997 | 108 | 0.140 |
Why?
| | Health Resources | 1 | 2018 | 120 | 0.140 |
Why?
| | Cholesterol, HDL | 2 | 2015 | 203 | 0.140 |
Why?
| | Vomiting | 1 | 1997 | 128 | 0.140 |
Why?
| | Hysterectomy | 1 | 1997 | 119 | 0.140 |
Why?
| | Severity of Illness Index | 2 | 2018 | 2736 | 0.130 |
Why?
| | Odds Ratio | 1 | 2019 | 1022 | 0.130 |
Why?
| | Surgical Wound Infection | 1 | 2019 | 281 | 0.130 |
Why?
| | Patient-Centered Care | 1 | 2021 | 493 | 0.130 |
Why?
| | Tandem Mass Spectrometry | 2 | 2024 | 450 | 0.130 |
Why?
| | Patient Participation | 1 | 2019 | 407 | 0.130 |
Why?
| | Phosphatidylethanolamines | 1 | 2016 | 74 | 0.130 |
Why?
| | Delivery of Health Care | 1 | 2023 | 892 | 0.130 |
Why?
| | Blotting, Western | 2 | 2016 | 1168 | 0.130 |
Why?
| | Phenotype | 1 | 2024 | 3050 | 0.120 |
Why?
| | Treatment Outcome | 6 | 2021 | 10163 | 0.120 |
Why?
| | Eating | 2 | 2021 | 365 | 0.120 |
Why?
| | Research Design | 2 | 2019 | 1038 | 0.120 |
Why?
| | Kidney Diseases | 1 | 2019 | 368 | 0.120 |
Why?
| | Exercise Therapy | 2 | 2017 | 414 | 0.120 |
Why?
| | Cost-Benefit Analysis | 1 | 2018 | 581 | 0.120 |
Why?
| | Indoles | 1 | 1997 | 367 | 0.120 |
Why?
| | Patient Compliance | 1 | 2019 | 562 | 0.120 |
Why?
| | Sleep Apnea Syndromes | 1 | 2015 | 78 | 0.120 |
Why?
| | Costs and Cost Analysis | 1 | 2015 | 208 | 0.120 |
Why?
| | Hypoglycemia | 1 | 2019 | 426 | 0.110 |
Why?
| | Income | 1 | 2015 | 189 | 0.110 |
Why?
| | Somatostatin | 1 | 2014 | 54 | 0.110 |
Why?
| | Logistic Models | 1 | 2019 | 1975 | 0.110 |
Why?
| | Pneumonia | 1 | 2019 | 599 | 0.110 |
Why?
| | Employment | 1 | 2015 | 167 | 0.110 |
Why?
| | Health Personnel | 1 | 2019 | 646 | 0.110 |
Why?
| | Fructose | 1 | 2014 | 107 | 0.110 |
Why?
| | Smoking | 2 | 2012 | 1463 | 0.110 |
Why?
| | Recovery of Function | 2 | 2015 | 643 | 0.110 |
Why?
| | Metabolic Diseases | 1 | 2014 | 106 | 0.100 |
Why?
| | Cost of Illness | 1 | 2015 | 288 | 0.100 |
Why?
| | Multicenter Studies as Topic | 1 | 2014 | 285 | 0.100 |
Why?
| | Qualitative Research | 1 | 2019 | 1205 | 0.100 |
Why?
| | C-Reactive Protein | 1 | 2015 | 396 | 0.100 |
Why?
| | Oxygen Consumption | 4 | 2016 | 675 | 0.100 |
Why?
| | Fatty Acids, Monounsaturated | 1 | 2012 | 51 | 0.100 |
Why?
| | Aged, 80 and over | 3 | 2019 | 7040 | 0.100 |
Why?
| | Homeostasis | 1 | 2016 | 605 | 0.100 |
Why?
| | Models, Theoretical | 1 | 2016 | 546 | 0.100 |
Why?
| | Prospective Studies | 3 | 2019 | 7043 | 0.100 |
Why?
| | Mitochondria | 1 | 2018 | 844 | 0.090 |
Why?
| | Adult Children | 1 | 2011 | 23 | 0.090 |
Why?
| | Depressive Disorder, Major | 1 | 2015 | 347 | 0.090 |
Why?
| | Practice Guidelines as Topic | 1 | 2019 | 1490 | 0.090 |
Why?
| | Placebos | 2 | 2009 | 201 | 0.090 |
Why?
| | Adipocytes | 1 | 2012 | 204 | 0.090 |
Why?
| | Age Factors | 1 | 2018 | 3117 | 0.090 |
Why?
| | Diabetes, Gestational | 1 | 2015 | 307 | 0.090 |
Why?
| | Health Behavior | 2 | 2023 | 740 | 0.090 |
Why?
| | Metabolomics | 1 | 2015 | 597 | 0.090 |
Why?
| | Sitagliptin Phosphate | 1 | 2010 | 32 | 0.090 |
Why?
| | Comorbidity | 1 | 2015 | 1540 | 0.090 |
Why?
| | Family Health | 1 | 2011 | 194 | 0.090 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2019 | 1271 | 0.090 |
Why?
| | Longevity | 1 | 2011 | 149 | 0.090 |
Why?
| | Quality of Life | 3 | 2019 | 2680 | 0.080 |
Why?
| | Mitochondria, Muscle | 2 | 2021 | 110 | 0.080 |
Why?
| | C-Peptide | 1 | 2010 | 163 | 0.080 |
Why?
| | Disease Progression | 3 | 2024 | 2603 | 0.080 |
Why?
| | Menopause | 1 | 2011 | 303 | 0.070 |
Why?
| | Leisure Activities | 1 | 2008 | 30 | 0.070 |
Why?
| | Delphi Technique | 2 | 2019 | 220 | 0.070 |
Why?
| | Blood Pressure | 1 | 2014 | 1733 | 0.070 |
Why?
| | Body Composition | 1 | 2011 | 656 | 0.070 |
Why?
| | Risk Assessment | 3 | 2015 | 3256 | 0.070 |
Why?
| | Predictive Value of Tests | 1 | 2012 | 1936 | 0.070 |
Why?
| | Fibrinogen | 2 | 2018 | 158 | 0.060 |
Why?
| | Cohort Studies | 4 | 2021 | 5369 | 0.060 |
Why?
| | Postoperative Complications | 1 | 1997 | 2479 | 0.060 |
Why?
| | Mass Screening | 1 | 2013 | 1152 | 0.060 |
Why?
| | Multivariate Analysis | 1 | 2009 | 1494 | 0.060 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2012 | 3618 | 0.060 |
Why?
| | Regression Analysis | 2 | 2019 | 983 | 0.060 |
Why?
| | Aging | 1 | 2015 | 1770 | 0.060 |
Why?
| | Metabolic Clearance Rate | 1 | 2004 | 103 | 0.060 |
Why?
| | Incidence | 3 | 2019 | 2619 | 0.060 |
Why?
| | Health Expenditures | 1 | 1986 | 184 | 0.060 |
Why?
| | Gene Expression Profiling | 2 | 2023 | 1687 | 0.060 |
Why?
| | Prognosis | 2 | 2023 | 3780 | 0.050 |
Why?
| | Retrospective Studies | 2 | 2019 | 14460 | 0.050 |
Why?
| | Depression | 1 | 2012 | 1289 | 0.050 |
Why?
| | Hormones | 1 | 2004 | 140 | 0.050 |
Why?
| | Mice, Inbred C57BL | 1 | 2013 | 5257 | 0.050 |
Why?
| | Menstrual Cycle | 1 | 2003 | 124 | 0.050 |
Why?
| | Alcohol Drinking | 1 | 2009 | 749 | 0.050 |
Why?
| | Parents | 1 | 2011 | 1306 | 0.050 |
Why?
| | Gastrointestinal Diseases | 1 | 2024 | 197 | 0.050 |
Why?
| | Wakefulness | 2 | 2015 | 114 | 0.050 |
Why?
| | Eligibility Determination | 1 | 2023 | 63 | 0.050 |
Why?
| | Lactic Acid | 1 | 2003 | 295 | 0.050 |
Why?
| | Animals | 3 | 2024 | 34501 | 0.050 |
Why?
| | Proportional Hazards Models | 2 | 2017 | 1208 | 0.050 |
Why?
| | Acute Disease | 1 | 2024 | 968 | 0.050 |
Why?
| | Citric Acid Cycle | 1 | 2021 | 50 | 0.050 |
Why?
| | Subcellular Fractions | 1 | 2021 | 80 | 0.050 |
Why?
| | Injections, Subcutaneous | 1 | 2021 | 145 | 0.040 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 2020 | 53 | 0.040 |
Why?
| | Motor Activity | 2 | 2015 | 667 | 0.040 |
Why?
| | Kinetics | 1 | 2004 | 1616 | 0.040 |
Why?
| | Protective Agents | 1 | 2020 | 38 | 0.040 |
Why?
| | Education | 1 | 2020 | 99 | 0.040 |
Why?
| | Proprotein Convertase 9 | 1 | 2020 | 68 | 0.040 |
Why?
| | Stearoyl-CoA Desaturase | 2 | 2010 | 62 | 0.040 |
Why?
| | Analysis of Variance | 2 | 2013 | 1271 | 0.040 |
Why?
| | Poisson Distribution | 1 | 2019 | 76 | 0.040 |
Why?
| | Time Factors | 3 | 2019 | 6503 | 0.040 |
Why?
| | Stakeholder Participation | 1 | 2019 | 76 | 0.040 |
Why?
| | Pregnancy | 2 | 2015 | 6297 | 0.040 |
Why?
| | E-Selectin | 1 | 2018 | 53 | 0.040 |
Why?
| | Consensus Development Conferences as Topic | 1 | 2018 | 28 | 0.040 |
Why?
| | Subcutaneous Fat | 1 | 2019 | 74 | 0.040 |
Why?
| | Probability | 1 | 2019 | 308 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2019 | 159 | 0.040 |
Why?
| | Chemokine CCL2 | 1 | 2018 | 117 | 0.040 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2018 | 132 | 0.040 |
Why?
| | Intra-Abdominal Fat | 1 | 2019 | 88 | 0.040 |
Why?
| | Cell Nucleus | 1 | 2020 | 579 | 0.040 |
Why?
| | Research | 1 | 2020 | 409 | 0.040 |
Why?
| | Leptin | 1 | 2018 | 218 | 0.030 |
Why?
| | Diet | 3 | 2012 | 1200 | 0.030 |
Why?
| | Case-Control Studies | 2 | 2017 | 3326 | 0.030 |
Why?
| | Metabolome | 1 | 2019 | 318 | 0.030 |
Why?
| | Adaptation, Physiological | 2 | 2010 | 514 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2019 | 428 | 0.030 |
Why?
| | Biological Transport | 1 | 2017 | 394 | 0.030 |
Why?
| | Rats | 1 | 2024 | 5168 | 0.030 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2016 | 95 | 0.030 |
Why?
| | Diet, Fat-Restricted | 1 | 2015 | 79 | 0.030 |
Why?
| | Melatonin | 1 | 2015 | 121 | 0.030 |
Why?
| | Longitudinal Studies | 2 | 2013 | 2697 | 0.030 |
Why?
| | Interleukin-6 | 1 | 2018 | 716 | 0.030 |
Why?
| | Kidney | 1 | 2022 | 1305 | 0.030 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2020 | 599 | 0.030 |
Why?
| | Fatty Acids | 1 | 2016 | 413 | 0.030 |
Why?
| | Calorimetry | 1 | 2013 | 67 | 0.030 |
Why?
| | Insulin Receptor Substrate Proteins | 1 | 2012 | 60 | 0.030 |
Why?
| | Risk | 1 | 2015 | 852 | 0.030 |
Why?
| | Glycerol | 1 | 2012 | 87 | 0.020 |
Why?
| | Sleep Wake Disorders | 1 | 2015 | 249 | 0.020 |
Why?
| | Algorithms | 1 | 2020 | 1616 | 0.020 |
Why?
| | RNA, Messenger | 2 | 2010 | 2674 | 0.020 |
Why?
| | Calorimetry, Indirect | 1 | 2010 | 80 | 0.020 |
Why?
| | Antidepressive Agents | 1 | 2012 | 221 | 0.020 |
Why?
| | Genetic Variation | 1 | 2015 | 934 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2022 | 5346 | 0.020 |
Why?
| | Palmitic Acid | 1 | 2010 | 40 | 0.020 |
Why?
| | Nicotine | 1 | 2012 | 303 | 0.020 |
Why?
| | Polysomnography | 1 | 2010 | 159 | 0.020 |
Why?
| | Retinoid X Receptor gamma | 1 | 2009 | 4 | 0.020 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2012 | 380 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2019 | 2506 | 0.020 |
Why?
| | PPAR alpha | 1 | 2009 | 59 | 0.020 |
Why?
| | Bicycling | 1 | 2010 | 118 | 0.020 |
Why?
| | Coronary Disease | 1 | 2011 | 384 | 0.020 |
Why?
| | Phospholipids | 1 | 2010 | 209 | 0.020 |
Why?
| | Women's Health | 1 | 2011 | 363 | 0.020 |
Why?
| | Phosphorylation | 1 | 2012 | 1681 | 0.020 |
Why?
| | Reference Values | 1 | 2009 | 780 | 0.020 |
Why?
| | Mice | 1 | 2024 | 16579 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 937 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2015 | 2266 | 0.020 |
Why?
| | Adiposity | 1 | 2012 | 505 | 0.020 |
Why?
| | Patient Education as Topic | 1 | 2011 | 734 | 0.020 |
Why?
| | Genotype | 1 | 2011 | 1831 | 0.020 |
Why?
| | Infant Care | 1 | 1986 | 46 | 0.020 |
Why?
| | Infertility | 1 | 1986 | 50 | 0.020 |
Why?
| | Health Promotion | 1 | 2011 | 717 | 0.010 |
Why?
| | Delivery, Obstetric | 1 | 1986 | 135 | 0.010 |
Why?
| | Maternal Health Services | 1 | 1986 | 95 | 0.010 |
Why?
| | Contraception | 1 | 1986 | 151 | 0.010 |
Why?
| | Anaerobic Threshold | 1 | 2003 | 27 | 0.010 |
Why?
| | Follicular Phase | 1 | 2003 | 40 | 0.010 |
Why?
| | Abortion, Induced | 1 | 1986 | 98 | 0.010 |
Why?
| | Spectrophotometry, Ultraviolet | 1 | 2003 | 80 | 0.010 |
Why?
| | Luteal Phase | 1 | 2003 | 44 | 0.010 |
Why?
| | Catecholamines | 1 | 2003 | 97 | 0.010 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2011 | 2065 | 0.010 |
Why?
| | Heart Rate | 1 | 2003 | 804 | 0.010 |
Why?
| | Infant, Newborn | 1 | 1986 | 5687 | 0.010 |
Why?
|
|
Perreault's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|